Open-Label Treatment Extension of Protocol MNTX 302

Completed · Phase 3

Conditions studied: Terminal Illness

In brief

This is a 3 month open-label extension study that allows patients who completed Protocol MNTX 302 to receive SC MNTX.

Key facts

Study ID

NCT01367613

Run by

Bausch Health Americas, Inc.

People needed

89

Starts

2004-03-01

Expected to finish

2006-01-01

Last updated by the study team

2019-11-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must be enrolled and consented within 28 days of the end of study visit of MNTX 302 and 14 or more days from first dose of study drug in MNTX 302.
• Negative pregnancy test
• Stable vital signs

You may not qualify if…

• Women who are pregnant and/or nursing
• Received any investigational product, other than MNTX, in the past 30 days
• Evidence of fecal impaction
• Clinically significant active diverticular disease

Where it is running

• Progenics Pharmaceuticals, Inc. — Tarrytown, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.